|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:head_and_neck_squamous_cell_carcinoma
melanoma
Hodgkin lymphoma
renal cell carcinoma
|
|
gptkbp:category
|
immunotherapy
|
|
gptkbp:contraindication
|
severe autoimmune disease
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
gptkb:Regeneron_Pharmaceuticals
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:enhance
|
T cell activity
|
|
gptkbp:example
|
gptkb:pembrolizumab
gptkb:cemiplimab
gptkb:nivolumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
anti-PD-1 antibodies
|
|
gptkbp:mechanismOfAction
|
block PD-1/PD-L1 interaction
|
|
gptkbp:monitors
|
immune-related adverse events
|
|
gptkbp:regulates
|
immune response
|
|
gptkbp:relatedTo
|
anti-PD-L1 antibodies
|
|
gptkbp:sideEffect
|
fatigue
hepatitis
rash
inflammatory bowel disease
pneumonitis
endocrinopathies
|
|
gptkbp:target
|
PD-1 protein
|
|
gptkbp:usedFor
|
immunotherapy
|
|
gptkbp:usedIn
|
combination drug
|
|
gptkbp:bfsParent
|
gptkb:programmed_cell_death_protein_1_(PD-1)
|
|
gptkbp:bfsLayer
|
6
|